Fusion Health Care, a pharma company based at Hyderabad, has announced the launch of its favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.
The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have issued draft antimicrobial prescribing guidance on impetigo.